3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
8
fludarabine
4
Cyclophosphamide
4
amatuximab
3
Thiotepa
3
Nivolumab
3
Ipilimumab
3
Hyperthermic Intraperitoneal Chemotherapy
3
Filgrastim
3
Carboplatin
3
budigalimab
2
belinostat
2
SS1(dsFv)PE38
2
Platinum
2
Peripheral Blood Stem Cell Transplantation
2
Cisplatin
2
1,2-diaminocyclohexaneplatinum II citrate
2
venetoclax
1
talazoparib
1
sodium thiosulfate
1
rovalpituzumab tesirine
1
ribociclib
1
rebastinib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine phosphate
1
epacadostat
1
durvalumab
1
bosutinib
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Blood Component Removal
×
Other solid neoplasm
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled